Clinical Scorecard: The Connection Between Post-Streptococcal Autoimmunity and Epstein–Barr Virus as a Possible Contributor to Multiple Sclerosis
At a Glance
Category
Detail
Condition
Multiple sclerosis (MS) potentially triggered by Epstein–Barr virus (EBV) infection
Key Mechanisms
EBV latent-lytic cycling driving MS disease activity via molecular mimicry; analogy to group A streptococcus (GAS) triggering acute rheumatic fever (ARF)
Target Population
Individuals exposed to EBV, especially those with infectious mononucleosis (IM) history
Care Setting
Infectious disease and neurology clinical settings; potential for antiviral treatment and vaccination
Key Highlights
EBV infection is necessary but insufficient alone to cause MS; latent EBV reactivation may drive MS attacks.
History of IM doubles the risk of developing MS compared to asymptomatic EBV seroconversion.
Treating acute IM with antivirals may serve as primary prevention of MS; continuous antiviral therapy may act as secondary prevention.
Guideline-Based Recommendations
Diagnosis
Recognize EBV exposure and history of IM as risk factors for MS development.
Use brain MRI to detect preexisting white matter lesions in suspected MS cases.
Management
Develop and implement effective antiviral therapies for acute IM to reduce EBV viral load.
Consider long-term antiviral prophylaxis targeting latent EBV in MS patients to prevent further attacks.
Promote EBV vaccination as a preventive strategy against IM and MS.
Monitoring & Follow-up
Monitor EBV antibody and T-cell receptor responses to assess disease activity.
Track MS disease progression and lesion formation via MRI.
Risks
Complications of IM include upper airway obstruction, meningoencephalitis, hematologic abnormalities, myocarditis, and splenic rupture.
Delayed or absent treatment of IM may increase risk of MS development and other EBV-associated conditions.
Patient & Prescribing Data
Patients with acute infectious mononucleosis and established multiple sclerosis
Antiviral treatment of acute IM may prevent MS onset; continuous antiviral therapy may reduce MS relapses by targeting latent EBV in memory B cells.
Clinical Best Practices
Early identification and treatment of acute IM with antivirals to reduce EBV viral load and immune dysregulation.
Use MRI imaging to detect subclinical MS lesions prior to clinical symptom onset.
Advocate for EBV vaccination to prevent IM and potentially reduce MS incidence.
Educate patients with IM about complications and advise avoidance of contact sports for at least three weeks.
Utilize population registries to evaluate the impact of antiviral treatment on MS incidence.
by Gavin Giovannoni, Olivia Payne, Ester Valero-Hernández, Angray S Kang, Bavneet Kaur Singh, David Baker, Kathryn Harris, Teresa Cutino-Moguel, Louisa K James, Benjamin Michael Bloom
